

Elisabeth Diver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8270976/publications.pdf>

Version: 2024-02-01

29
papers

594
citations

687363

13
h-index

610901

24
g-index

30
all docs

30
docs citations

30
times ranked

914
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 888-895.	4.9	113
2	Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated With Reduced Morbidity and Similar Survival Outcomes Compared With Laparotomy. Journal of Minimally Invasive Gynecology, 2017, 24, 402-406.	0.6	79
3	Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: A SEER analysis. Gynecologic Oncology, 2013, 131, 46-51.	1.4	53
4	Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecologic Oncology, 2013, 129, 332-335.	1.4	39
5	Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology, 2017, 147, 250-256.	1.4	33
6	Minimally Invasive Staging Surgery in Women with Early-Stage Endometrial Cancer: Analysis of the National Cancer Data Base. Annals of Surgical Oncology, 2017, 24, 1677-1687.	1.5	32
7	Adherence to Evidence-Based Guidelines for Preoperative Testing in Women Undergoing Gynecologic Surgery. Obstetrics and Gynecology, 2010, 116, 694-700.	2.4	25
8	Uterine Leiomyosarcoma. International Journal of Gynecological Cancer, 2013, 23, 1036-1043.	2.5	20
9	Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old. Journal of Geriatric Oncology, 2018, 9, 516-519.	1.0	20
10	Trends in the Treatment of Uterine Leiomyosarcoma in the Medicare Population. International Journal of Gynecological Cancer, 2015, 25, 453-458.	2.5	19
11	Racial disparities in survival in malignant germ cell tumors of the ovary. Gynecologic Oncology, 2016, 140, 463-469.	1.4	17
12	Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience. Modern Pathology, 2022, 35, 688-696.	5.5	17
13	Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Gynecologic Oncology, 2018, 148, 168-173.	1.4	14
14	Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States. Journal of Minimally Invasive Gynecology, 2020, 27, 482-488.	0.6	13
15	An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial. Gynecologic Oncology, 2021, 162, S17-S18.	1.4	13
16	Changes in clinical presentation of postterm choriocarcinoma at the New England Trophoblastic Disease Center in recent years. Gynecologic Oncology, 2013, 130, 483-486.	1.4	12
17	Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium. Obstetrics and Gynecology, 2015, 126, 815-822.	2.4	12
18	Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. Gynecologic Oncology, 2015, 139, 77-83.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 66-72.	2.5	11
20	Brain Metastases from Endometrial Cancer: Clinical Characteristics, Outcomes, and Review of the Literature. <i>World Neurosurgery</i> , 2021, 147, e32-e39.	1.3	9
21	Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit. <i>Gynecologic Oncology</i> , 2020, 159, 118-128.	1.4	8
22	Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer. <i>Gynecologic Oncology</i> , 2017, 144, 136-139.	1.4	7
23	Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1118-1123.	2.5	6
24	Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. <i>Gynecologic Oncology</i> , 2021, 161, 275-281.	1.4	5
25	ASCO 2019 meeting review. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e107.	2.2	2
26	Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous Thromboembolism. <i>JAMA Network Open</i> , 2020, 3, e208019.	5.9	1
27	Abstract CT157: An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial. , 2019, , .		1
28	Age and racial differences in the presentation of gestational trophoblastic neoplasia. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 194-202.	2.5	1
29	Abstract CT157: An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial. , 2019, , .		0